| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Feras Ali Mustaf. Use of Clozapine in the General Hospital. Psychopharmacology bulletin. vol 50. issue 3. 2021-11-08. PMID:32733115. |
patients with treatment-resistant schizophrenia receiving clozapine therapy are at risk of potentially serious complications in the general hospital setting, due to the complex pharmacokinetic and pharmacodynamic profile of clozapine. |
2021-11-08 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yuji Yada, Masafumi Kodama, Yoshiki Kish. Clinical Utility and Safety of Slower-than-Recommended Titration of Clozapine for Treatment-Resistant Schizophrenia: a Retrospective Cohort Study. The Psychiatric quarterly. vol 92. issue 2. 2021-11-08. PMID:32889690. |
clinical utility and safety of slower-than-recommended titration of clozapine for treatment-resistant schizophrenia: a retrospective cohort study. |
2021-11-08 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yuji Yada, Masafumi Kodama, Yoshiki Kish. Clinical Utility and Safety of Slower-than-Recommended Titration of Clozapine for Treatment-Resistant Schizophrenia: a Retrospective Cohort Study. The Psychiatric quarterly. vol 92. issue 2. 2021-11-08. PMID:32889690. |
consequently, we aimed to investigate the clinical utility and safety of slower-than-recommended titration of clozapine for treatment-resistant schizophrenia. |
2021-11-08 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yuji Yada, Masafumi Kodama, Yoshiki Kish. Clinical Utility and Safety of Slower-than-Recommended Titration of Clozapine for Treatment-Resistant Schizophrenia: a Retrospective Cohort Study. The Psychiatric quarterly. vol 92. issue 2. 2021-11-08. PMID:32889690. |
we conducted a retrospective chart review of 152 inpatients with treatment-resistant schizophrenia who had been newly started on clozapine in a tertiary psychiatric public hospital between april 2012 and march 2018. |
2021-11-08 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yuji Yada, Masafumi Kodama, Yoshiki Kish. Clinical Utility and Safety of Slower-than-Recommended Titration of Clozapine for Treatment-Resistant Schizophrenia: a Retrospective Cohort Study. The Psychiatric quarterly. vol 92. issue 2. 2021-11-08. PMID:32889690. |
therefore, it may not be a beneficial option in terms of safe clozapine continuation when starting clozapine for treatment-resistant schizophrenia. |
2021-11-08 |
2023-08-13 |
Not clear |
| Teodorescu Andreea, Ifteni Petru, Ana Aliana Miron, Petric Paula-Simina, Dima Loren. Clozapine for Treatment-Refractory Aggressive Behavior. The Psychiatric quarterly. vol 92. issue 2. 2021-11-08. PMID:32918660. |
clozapine, the gold standard for trs (treatment resistant schizophrenia) is effective in controlling aggression. |
2021-11-08 |
2023-08-13 |
Not clear |
| Teodorescu Andreea, Ifteni Petru, Ana Aliana Miron, Petric Paula-Simina, Dima Loren. Clozapine for Treatment-Refractory Aggressive Behavior. The Psychiatric quarterly. vol 92. issue 2. 2021-11-08. PMID:32918660. |
off 19,000 patients admitted during the study period, 504 patients (2,4%) with a diagnosis other than schizophrenia or schizoaffective disorder received clozapine for aggressiveness (89.5%). |
2021-11-08 |
2023-08-13 |
Not clear |
| Sujin Kim, Seoyoung Kim, Ah Young Choe, Euitae Ki. Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study. Psychiatry investigation. vol 18. issue 10. 2021-11-05. PMID:34619819. |
associations of clozapine use with psychosocial functioning and quality of life in patients with schizophrenia: a community-based cross-sectional study. |
2021-11-05 |
2023-08-13 |
Not clear |
| Sujin Kim, Seoyoung Kim, Ah Young Choe, Euitae Ki. Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study. Psychiatry investigation. vol 18. issue 10. 2021-11-05. PMID:34619819. |
this study examined the relationship of clozapine use with psychosocial functioning and quality of life in patients with schizophrenia in a real-world setting. |
2021-11-05 |
2023-08-13 |
Not clear |
| Lennart Kyllesø, Robert Løvsletten Smith, Øystein Karlstad, Ole A Andreassen, Espen Molde. Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. CNS drugs. vol 35. issue 9. 2021-11-04. PMID:34417726. |
clozapine is an effective drug for the management of schizophrenia that has not responded to other agents, but some patients experience insufficient or adverse effects and discontinue treatment. |
2021-11-04 |
2023-08-13 |
Not clear |
| Espen Molde. Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies. Expert opinion on drug metabolism & toxicology. vol 17. issue 10. 2021-11-04. PMID:34461790. |
therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies. |
2021-11-04 |
2023-08-13 |
Not clear |
| Espen Molde. Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies. Expert opinion on drug metabolism & toxicology. vol 17. issue 10. 2021-11-04. PMID:34461790. |
clozapine (clz) is the superior drug in treatment of schizophrenia. |
2021-11-04 |
2023-08-13 |
Not clear |
| Michelle Iris Jakobsen, Ole Jakob Storebø, Stephen Fitzgerald Austin, Jimmi Nielsen, Erik Simonse. Patients' and psychiatrists' perspectives on clozapine treatment-a scoping review protocol. BMJ open. vol 11. issue 10. 2021-11-03. PMID:34620673. |
the atypical antipsychotic clozapine has shown superior efficacy compared with other antipsychotics and is the gold standard for treating otherwise treatment resistant schizophrenia. |
2021-11-03 |
2023-08-13 |
human |
| Anand Alagappan, Rosaleen Baruah, Alastair Cockburn, Euan A Sandiland. Paradoxical refractory hypotension following adrenaline administration in a patient taking clozapine. BMJ case reports. vol 14. issue 11. 2021-11-03. PMID:34725057. |
clozapine is a potent antipsychotic commonly used for refractory schizophrenia. |
2021-11-03 |
2023-08-13 |
Not clear |
| Bridson Tahnee, Abeysundera Hesitha, Arunachalam Arulmathy, Lam Anthea, Mora Linda, McGorry Patrick, O'Donoghue Bria. The use of clozapine in a rural and remote region of Australia. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 29. issue 2. 2021-11-01. PMID:33354992. |
clozapine is the most effective antipsychotic available for treatment-resistant schizophrenia. |
2021-11-01 |
2023-08-13 |
Not clear |
| Chuanjun Zhuo, Yong Xu, Haibo Wang, Chunhua Zhou, Jian Liu, Xiaocui Yu, Hailin Shao, Hongjun Tian, Tao Fang, Qianchen Li, Jiayue Chen, Shuli Xu, Xiaoyan Ma, Weiliang Yang, Cong Yao, Bo Li, Anqu Yang, Yuhui Chen, Guoyong Huang, Chongguang Li. Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. Journal of affective disorders. vol 295. 2021-11-01. PMID:34464878. |
clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. |
2021-11-01 |
2023-08-13 |
Not clear |
| Tsukasa Murata, Taiki Negishi, Kuninori Yuki, Sachiko Omori, Hiroko Ab. Post-clozapine in a clinical setting: A retrospective case note review in Kumamoto, Japan (2009-2019). Asian journal of psychiatry. vol 65. 2021-11-01. PMID:34543721. |
we investigated antipsychotic medications, patient status, and dsp episodes before, during, and after clozapine treatment using medical records of 30 schizophrenia patients (mean age, 51 years; mean illness duration before clozapine treatment, 24 years; mean clozapine treatment duration, 1.6 years), who discontinued clozapine between 2009 and 2019. |
2021-11-01 |
2023-08-13 |
Not clear |
| Ivan D Montoya, Frank Vocc. Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. Journal of dual diagnosis. vol 3. issue 3-4. 2021-10-28. PMID:19194522. |
others have evaluated the anti-smoking effect of medications (e.g., clozapine, haloperidol) used for the treatment of schizophrenia. |
2021-10-28 |
2023-08-12 |
Not clear |
| Şevin Hun Şenol, Gamze Gürcan, Aygün Ertuğrul, Sevilay Karahan, A Elif Anıl Yağcıoğl. [Augmentation of Clozapine Due to Inadequate Treatment Response in Schizophrenia: Comparison of Patients with Augmented and Non-augmented Treatments]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 1. 2021-10-28. PMID:34181738. |
[augmentation of clozapine due to inadequate treatment response in schizophrenia: comparison of patients with augmented and non-augmented treatments]. |
2021-10-28 |
2023-08-13 |
Not clear |
| Şevin Hun Şenol, Gamze Gürcan, Aygün Ertuğrul, Sevilay Karahan, A Elif Anıl Yağcıoğl. [Augmentation of Clozapine Due to Inadequate Treatment Response in Schizophrenia: Comparison of Patients with Augmented and Non-augmented Treatments]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 1. 2021-10-28. PMID:34181738. |
clozapine is considered to be a gold standard antipsychotic in treatment resistant schizophrenia. |
2021-10-28 |
2023-08-13 |
Not clear |